Key Takeaways:
- The science outruns the payers. Multiplex molecular diagnostics have advanced far faster than coverage policy. By most estimates, the science runs five to ten years ahead of payers, and that gap now shows up as denials, documentation requests, and recoupments.
- The rules depend entirely on the payer. Whether a lab needs a MolDX Z code, a technical assessment, or prior authorization changes by Medicare Administrative Contractor (MAC), by state, and by commercial plan. There is no single national policy.
- Most denials are about medical necessity and coding, not the test itself. The top drivers are largely preventable before a claim is ever submitted: weak medical-necessity documentation, overutilization, unbundling or downcoding, and diagnosis-to-test mismatches.
- Get your house in order first. Front-end eligibility checks, payer-specific claim scrubbing, disciplined appeals, and tracked KPIs protect revenue far better than chasing denials after the fact.
Why Is Multiplex Testing Reimbursement So Complicated?
Multiplex molecular testing gives labs a powerful way to detect multiple pathogens from a single specimen, but getting paid for it has become one of the hardest operational problems in the lab.
Multiplex panels are not new; the technology has evolved over the last 15 to 20 years. Utilization spiked during the COVID-19 pandemic, when PCR-based multiplex tests proliferated and labs adopted the technology at scale. More testing brought more payer scrutiny, and now that the pandemic surge has passed, payers are catching up with policy, denials, and audits.
In a recent webinar hosted by Applied BioCode, the maker of the Barcoded Magnetic Bead (BMB) multiplex platform and BioCode syndromic respiratory and gastrointestinal panels, Ann Lambrix, Executive Director of RCM Consulting at Lighthouse Lab Services, walked lab and billing leaders through how to navigate this landscape. With more than 23 years in medical insurance and billing, Lambrix framed the core tension plainly: the science is typically five to ten years ahead of the payers. What follows distills her practical guidance for reducing denials before claims go out the door.
Who Decides Coverage: MolDX vs. Everyone Else?
There is no one-size-fits-all reimbursement rule in the United States. Lambrix breaks the landscape into three buckets: Medicare, state and managed plans, and commercial payers.
On the Medicare side, seven Medicare Administrative Contractors (MACs) administer claims across the jurisdictions. Four of them participate in MolDX (the Molecular Diagnostic Exchange), among them CGS, Palmetto, and Noridian, while three do not: Novitas, First Coast, and NGS.
For labs billing a MolDX MAC, infectious disease testing (rolled into the program around March to April 2022) generally requires a Z code, a unique identifier that ties a specific test to the specific lab performing it. The Z code pairs with the CPT code. If a test is not FDA-approved, it will likely also require a technical assessment, the substantive review of clinical validity, analytical validity, and clinical utility that determines whether the test gets covered.
A common misconception is that no policy means no risk. Lambrix is emphatic that the opposite is true. Even in non-MolDX jurisdictions, MACs can invoke reasonable-and-necessary criteria after the fact. Medicare is a “pay-and-chase” payer, meaning a paid claim is not a settled claim. Non-MolDX contractors such as Novitas are tightening scrutiny, requesting documentation, and clawing back prior payments.
Commercial payers are moving the same direction. UnitedHealthcare and Humana have subscribed to MolDX-style requirements, with UnitedHealthcare’s commercial policy calling for a Z code and technical assessment for the relevant respiratory and GI codes. More payers are also requiring prior authorization for infectious disease testing.
How Do You Code Multiplex Panels Correctly?
Coding is where many labs unknowingly create denial risk. Respiratory and GI panels have bundled CPT codes tied to the number of pathogen targets reported:
- Respiratory: 87631 to 87633, by target count (3 to 5, 6 to 11, and 12+).
- Gastrointestinal: 87505 to 87507, also by target count.
- STI: a bundled code now exists for chlamydia, gonorrhea, and trichomonas.
When a bundled code exists, do not unbundle it into individual targets; bill the panel code. Medicare may pay individually billed targets, but because of pay-and-chase, that payment can later be audited and recouped. Lambrix also flagged downcoding, for example billing 87631 when a 12-plus-target 87633 was performed, as a growing audit trigger, because the claim no longer reflects the test that is actually run.
For panels without a bundled code, such as UTI/wound, labs have used 87798 (infectious agent detection, not otherwise specified), but that path is closing as payers push toward 87801 under a “one test equals one code” stance. Lambrix’s view is that the real question is what the physician ordered: a panel, or individual targets. Because platforms differ in how they handle this, it helps that systems like Applied BioCode’s BioCode MDx-3000 can automatically mask results for targets that weren’t ordered – though, as Lambrix stressed, labs must always result what was ordered and bill to match.
What Are the Top Denial Drivers?
Lambrix identified the most common reasons multiplex claims get denied or recouped:
- Lack of medical-necessity documentation: This is the single biggest driver. If the ordering record doesn’t clearly show why the panel was needed and how it would change management, payers have grounds to deny.
- Overutilization: Payers now use AI on the back end to flag utilization spikes (codes such as 87798 have drawn attention), then request documentation to justify them.
- Incorrect CPT coding or unit reporting: Unbundling, downcoding, or exceeding a payer’s medically unlikely edit (MUE), including unpublished limits, invites denials.
- Diagnosis-to-test mismatches: The CPT code says what was done; the diagnosis (ICD-10) code says why. They have to align with the payer’s coverage criteria.
- Frequency edits, duplicate testing, and missing or unsigned orders: Sometimes the denial is “silly,” Lambrix noted, such as a missing signed order, and can be overturned with complete documentation.
How Can Labs Reduce Denials Before Submission?
The throughline of Lambrix’s guidance is to move the work to the front end. Her core recommendations include:
- Verify eligibility and coverage for each patient and payer. A contract is not a guarantee of coverage.
- Identify prior-auth and Z-code requirements up front, before the test is run.
- Scrub claims against current policy before submission.
- Build a mechanism to respond to audit and documentation requests. Unanswered requests, she warned, are a total loss and invite further scrutiny.
- Make appeals policy-aligned and complete, not sloppy. Treat denials as clues: a recurring “not medically necessary” denial signals an underlying policy to fix on the front end, not a code to keep rebilling.
- Measure billing and collections KPIs. What gets managed gets measured.
- Favor patient-centric, targeted panels. Coverage for expanded panels (more than five targets) is limited across most plans, while smaller, syndrome-appropriate panels tend to fare better. Under Medicare’s outpatient LCD 39001, routine-care respiratory and GI testing generally isn’t eligible, whereas high-acuity scenarios (immunocompromised, ICU, or severe disease) carry a high probability of coverage. Inpatient testing follows a different path, bundled into the hospital’s DRG payment.
What Should Lab Leaders Watch Next?
Lambrix expects more structure, not less. She anticipates additional MACs and commercial plans aligning with MolDX over time, even amid a recent leadership transition at the program. She also flagged PAMA and Clinical Laboratory Fee Schedule reporting, with the data-reporting period running January through June 30, 2025, private-payer data due by July 31, and rate adjustments likely beginning around 2027, along with continued payer scrutiny of laboratory-developed tests even after federal FDA oversight of LDTs was rescinded.
The Bottom Line
For labs running multiplex molecular panels, reimbursement is now as much a strategic discipline as the science itself. Understanding your payer mix, coding to the test you actually performed, documenting medical necessity, and managing denials proactively are what protect the return on a lab’s testing investment.
Interested in watching the full webinar? You can find it here.
Samba Scientific helps life science and diagnostics companies turn expert sessions like this into high-value content and demand. To learn how our webinar and video production services can extend the reach of your next event, get in touch with our team.
